About this trial

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Eligibility criteria

Qualifiers

Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.

Receiving clinical care at Yale Rheumatology clinics

Disqualifiers

Unable to provide informed consent

No patients will be excluded based on gender or ethnicity or pregnancy status.

Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.

Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

5,000 Participants
are grouped into 1 trial group

Locations

1
Yale New Haven Hospital06510, New HavenConnecticut, United States

Sponsors and collaborators

Yale University

Lead sponsor

Rheumatology Research Foundation

Collaborator